Contact us
Appointment
Appointment

Biohaven/Pfizer 311/312: children & teens migraine attacks

Biohaven / Pfizer Study 311–312 is a clinical research study for children and teenagers who experience migraine attacks. This study is helping researchers learn whether an investigational study medicine called rimegepant, taken as an oral dissolving tablet, can help relieve migraine pain and related symptoms in younger patients.

Migraine Clinical Trial for
Children & Teens (Ages 6–17)

By participating, your child will receive care from a dedicated medical research team and help advance migraine treatment options for children and teens affected by this condition.

Frequently Asked Questions

What is a migraine in children and teens?

Migraines in children and adolescents are a neurological condition that can cause moderate to severe headaches, often accompanied by nausea and sensitivity to light, sound, or physical activity. These migraines can disrupt school, activities, and daily life.
Clinical trials help researchers learn whether new treatments are safe and effective for children and teens. Many migraine treatments are developed for adults first, so studies like this are essential to improve care options for younger patients.
Participants receive care from a dedicated medical team and undergo scheduled study visits and evaluations. All study-related care is provided at no cost, and the study team will guide families through every step of the process.

Accessibility Toolbar